Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask The Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
FAQs
Advertising
PR Newswire
Report Store
UsernamePublicRestriction
Tags:
Medical Device Regulation Business Strategies

People Briefs

This article was originally published in The Gray Sheet

  • News

Executive Summary

Epigenomics, RainDance, and Brightree name new leadership, and more personnel news from around the industry.

You may also be interested in...



Global Medtech Guidance Tracker: February 2021

Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Thirty-eight guidance documents have been posted on the tracker since its last update.

Merck KGaA's Diversified Business Model Proves Its Worth During Pandemic

Germany’s Merck KGaA rapidly expanded its life sciences services business to support the manufacture of COVID-19 vaccines during 2020, and also expects cancer and multiple sclerosis products to fuel its sales growth in coming years.

UCB Aims To Tailor Myasthenia Gravis Therapy Options To Patients

Belgium’s UCB Pharma is expecting progress with new candidates for myasthenia gravis, psoriasis and osteoporosis this year.

Table

View full table

Topics

Related Companies

Tags:
Medical Device Regulation Business Strategies
UsernamePublicRestriction

Register

OM008605

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By